Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

DiNardo CD., Stein AS., Stein EM., Fathi AT., Frankfurt O., Schuh AC., Doehner H., Martinelli G., Raffoux E., Tan P., Zeidan A., de Botton S., Kantarjian HM., Stone RM., Lam D., Wang X., Gong J., Kapsalis SM., Hickman D., Zhang V., Winkler T., Daigle S., Vyas P.

DOI

10.1016/j.clml.2019.07.090

Type

Conference paper

Publication Date

09/2019

Volume

19

Pages

S217 - S218

Keywords

acute myeloid leukemia, azacitidine, ivosidenib, mIDH1 molecular clearance, complete remission, AML

Permalink Original publication